Table 2 Changes in clinical parameters from baseline to 12 months after ADT for M0CSPC patients with osteoporosis
|  | ZOL 5 mg group (n = 26) |  | Control group (n = 16) |  | ||
|---|---|---|---|---|---|---|
Baseline | 12 months | % Change | Baseline | 12 months | % Change | |
BMD (g/cm2) | ||||||
 Lumbar spine | 1.06 ± 0.21 | 1.11 ± 0.25 | + 4.02 ± 3.61 d, f | 1.06 ± 0.16 | 1.03 ± 0.16 | −3.72 ± 3.91 b |
 Femoral neck | 0.73 ± 0.09 | 0.73 ± 0.10 | + 0.99 ± 4.41 e | 0.78 ± 0.11 | 0.76 ± 0.09 | −1.52 ± 2.14 a |
Serum biochemistry | ||||||
 Creatinine (mg/dl) | 0.84 ± 0.16 | 0.81 ± 0.15 | − 2.65 ± 11.1 | 0.99 ± 0.27 | 0.97 ± 0.24 | + 1.22 ± 10.0 |
 eGFR (ml/min/1.73 m2) | 71.4 ± 16.0 | 73.5 ± 14.9 | + 4.21 ± 13.9 | 61.5 ± 15.3 | 61.5 ± 13.4 | −0.57 ± 10.8 |
 TRACP-5b (mU/dl) | 560.5 ± 198.6 | 247.2 ± 75.5 | −52.1 ± 19.0 d, f | 390.9 ± 227.9 | 545.4 ± 286.8 | + 36.4 ± 34.9 c |